01 June 2016
: Case report 
Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction , Educational Purpose (only if useful for a systematic review or synthesis)
Purva ChhibarBCDEF, Ziqiang ZhuBCDEF, Naga K.S. CheedellaBCDE, Rashid ChaudhryBCD, Jen Chin WangABCDOI: 10.12659/AJCR.896496
Am J Case Rep 2016; 17:371-374
Abstract
BACKGROUND: Patients receiving cancer treatment are at risk for hepatitis B virus (HBV) reactivation. Ifosfamide is an alkylating agent and is considered to be one of the important drugs for the treatment of metastatic sarcoma. No association of ifosfamide and HBV reactivation has been reported so far.
CASE REPORT: We report a case of a 61-year-old Asian man with metastatic retroperitoneal liposarcoma who was HBcAb positive and was treated with ifosfamide and dacarbazine, developed HBV reactivation secondary to ifosfamide requiring treatment with tenofovir. To the best of our knowledge, this is the first report describing HBV reactivation in a patient with positive HBcAb who was treated with ifosfamide.
CONCLUSIONS: We recommend close surveillance of possible HBV reactivation while employing ifosfamide chemotherapy.
Keywords: Antineoplastic Agents, Alkylating - adverse effects, Hepatitis B virus - physiology, Ifosfamide - adverse effects, Liposarcoma - drug therapy, Retroperitoneal Neoplasms - drug therapy, Virus Activation - drug effects
SARS-CoV-2/COVID-19
02 December 2022 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.938571
30 November 2022 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.938003
23 November 2022 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.938450
01 November 2022 : Case report 
Am J Case Rep 2022; 23:e937739
In Press
05 Dec 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938571
05 Dec 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938476
02 Dec 2022 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.938156
02 Dec 2022 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.937404
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
06 Dec 2021 : Case report 
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
17 Feb 2022 : Case report 
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399